Kyverna reports durable responses in early cell therapy trial for autoimmune disease

Kyverna Therapeutics announced new data from its cell therapy candidate targeting an autoimmune condition, marking progress toward a potential first‑in‑class product.

The results showed that a notable proportion of participants were able to remain off conventional treatments for a sustained period after receiving the therapy.

Researchers highlighted the durability of the response, suggesting the approach could provide a long‑term alternative to existing immunosuppressive regimens.

The company said the findings bring it a step closer to pursuing regulatory approval and launching larger trials.